Trial · NCT03088878
Participant flow84
How many started, completed or left each group, period by period.
21 to 40 of 84
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | Efficacy Population CLL (Parts 1 & 2) | CLL Phase 1b, Part 1: 4 mg/kg | 3 | |
| Overall Study | Efficacy Population CLL (Parts 1 & 2) | CLL Phase 1b, Part 1: 8 mg/kg | 3 | |
| Overall Study | Efficacy Population CLL (Parts 1 & 2) | CLL Phase 1b, Part 1: 16 mg/kg | 3 | |
| Overall Study | Efficacy Population CLL (Parts 1 & 2) | CLL Phase 1b, Part 1: 300 mg | 3 | |
| Overall Study | Efficacy Population CLL (Parts 1 & 2) | CLL Phase 1b, Part 1: 600 mg | 3 | |
| Overall Study | Efficacy Population CLL (Parts 1 & 2) | CLL Phase 1b, Part 2: 600mg | 16 | |
| Overall Study | Efficacy Population CLL (Parts 1 & 2) | CLL Phase 2, Part 3: 600 mg | 0 | |
| Overall Study | Efficacy Population CLL (Parts 1 & 2) | CLL Phase 2, Part 3: Ibrutinib Alone | 0 | |
| Overall Study | Efficacy Population (Part 3) | MCL Phase 1b, Part 1: 2mg/kg | 0 | |
| Overall Study | Efficacy Population (Part 3) | MCL Phase 1b, Part 1: 4mg/kg | 0 | |
| Overall Study | Efficacy Population (Part 3) | MCL Phase 1b, Part 1: 8mg/kg | 0 | |
| Overall Study | Efficacy Population (Part 3) | MCL Phase 1b, Part 1: 16 mg/kg | 0 | |
| Overall Study | Efficacy Population (Part 3) | MCL Phase 1b, Part 2: 600 mg | 0 | |
| Overall Study | Efficacy Population (Part 3) | CLL Phase 1b, Part 1: 2 mg/kg | 0 | |
| Overall Study | Efficacy Population (Part 3) | CLL Phase 1b, Part 1: 4 mg/kg | 0 | |
| Overall Study | Efficacy Population (Part 3) | CLL Phase 1b, Part 1: 8 mg/kg | 0 | |
| Overall Study | Efficacy Population (Part 3) | CLL Phase 1b, Part 1: 16 mg/kg | 0 | |
| Overall Study | Efficacy Population (Part 3) | CLL Phase 1b, Part 1: 300 mg | 0 | |
| Overall Study | Efficacy Population (Part 3) | CLL Phase 1b, Part 1: 600 mg | 0 | |
| Overall Study | Efficacy Population (Part 3) | CLL Phase 1b, Part 2: 600mg | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03088878/flow?page=2